Metastatic microcystic adnexal carcinoma with DNA sequencing results and response to systemic antineoplastic chemotherapy

20Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Microcystic adnexal carcinoma (MAC) is a rare cutaneous malignancy. Due to its rarity, the molecular characteristics and treatment for metastatic MAC remain undefined. Here we present, as far as we are aware, the first case of metastatic MAC with DNA sequencing results indicating a mutation in TP53 and chromosomal losses in cyclin dependent kinase inhibitor 2A (CDKN2A) and cyclin dependent kinase inhibitor 2B (CDKN2B). In addition, this is the first case of metastatic MAC with a documented objective response to systemic antineoplastic chemotherapy (carboplatin and paclitaxel) confirmed by positron emission tomography/computed tomography. Our case increases the very limited medical knowledge of this rare disease.

Cite

CITATION STYLE

APA

Chen, M. B., & Laber, D. A. (2017). Metastatic microcystic adnexal carcinoma with DNA sequencing results and response to systemic antineoplastic chemotherapy. Anticancer Research, 37(9), 5109–5111. https://doi.org/10.21873/anticanres.11929

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free